Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Ibrutinib

2

XVII.a Respiratory tract infection incl. pneumonia

2
Last update : 15/10/2016
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
The Lancet. Oncology 2016 Oct;17;1409-1418 2016 Oct
Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.
Bone marrow transplantation 2016 Jun;51;793-8 2016 Jun
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Blood 2015 Aug 06;126;739-45 2015 Aug 06

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies